多发性硬化和肠道症状:频率和管理障碍
Bertrand Bourre1, Charlotte Desprez2, Guillaume Gourcerol2
1Department of Neurology, CHU Rouen, CIC-CRB 1404, Rouen F-76000, France.
Multiple sclerosis and related disorders
|August 14, 2023
概括
肠道症状在多发性硬化症 (MS) 患者中很常见,但往往没有报告. 神经性肠道功能障碍 (NBD) 评分可以帮助识别这些问题,并鼓励报告以改善管理.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
背景情况:
- 肠道症状 (BSs) 很普遍,但在多发性硬化症 (MS) 中没有得到充分讨论.
- 这些症状对患有多发性硬化症的人来说造成了显著的痛苦.
- 了解BS的频率和预测因素对于患者护理至关重要.
研究的目的:
- 为了确定MS患者无法控制的肠道症状的频率.
- 为了确定寻求BSs医疗帮助的预测因素.
- 评估神经性肠道功能障碍 (NBD) 评分在BSs查中的有用性.
主要方法:
- 对369名多发性硬化患者进行了横截面调查.
- 收集的数据包括人口统计,临床MS细节,BS及其管理.
- 使用了神经性肠道功能障碍 (NBD) 评分.
主要成果:
- 几乎一半 (47.7%) 的MS患者报告了肠道症状.
- 很大一部分 (41%) 没有向医疗保健提供者报告BS,通常是由于不情愿.
- 较长的BS持续时间预测寻求帮助;女性性别,视力障碍,消化史和MS持续时间预测BSs.
- 在NBD得分 (>2) 中,正确识别了86%的BSs患者.
结论:
- 在MS患者群体中,肠道症状的检测不足,部分原因是患者不披露.
- 神经性肠道功能障碍 (NBD) 评分显示,增加BSs报告的可能性很大.
- 使用NBD得分可以改善成员国的肠道问题的识别和管理.
相关概念视频
Irritable Bowel Syndrome III: Medical and Nursing Management
240
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
240
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Chronic Bowel Disorders: Introduction
485
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
485
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
189
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
189
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Diarrhea-Predominant IBS
213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213


